Trial · NCT01771809
Results by group116
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 116
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to Treatment-Emergent Adverse Events (TEAEs) | SHP647 75 mg | Participants with any TEAE | 146 | Participants | |
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to Treatment-Emergent Adverse Events (TEAEs) | SHP647 225 mg | Participants with any TEAE | 147 | Participants | |
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to Treatment-Emergent Adverse Events (TEAEs) | SHP647 75 mg | Participants with any TESAE | 34 | Participants | |
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to Treatment-Emergent Adverse Events (TEAEs) | SHP647 225 mg | Participants with any TESAE | 40 | Participants | |
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to Treatment-Emergent Adverse Events (TEAEs) | SHP647 75 mg | Participants who withdrew treatment due to TEAE | 12 | Participants | |
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Who Withdrew From Treatment Due to Treatment-Emergent Adverse Events (TEAEs) | SHP647 225 mg | Participants who withdrew treatment due to TEAE | 23 | Participants | |
| Percentage of Participants With Mucosal Healing at Week 16 | SHP647 75 mg | 27.4 | Percentage of participants | ||
| Percentage of Participants With Mucosal Healing at Week 16 | SHP647 225 mg | 29.5 | Percentage of participants | ||
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 75 mg | Baseline | 6398.62 | Standard Deviation 8584.412 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 225 mg | Baseline | 8064.41 | Standard Deviation 10629.768 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 75 mg | Week 4 | 5496.56 | Standard Deviation 4026.759 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 225 mg | Week 4 | 16787.31 | Standard Deviation 7807.292 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 75 mg | Week 8 | 6245.79 | Standard Deviation 3371.708 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 225 mg | Week 8 | 20345.29 | Standard Deviation 9286.956 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 75 mg | Week 12 | 9038.72 | Standard Deviation 5540.836 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 225 mg | Week 12 | 23915.87 | Standard Deviation 10434.073 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 75 mg | Week 16 | 10445.24 | Standard Deviation 6387.004 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 225 mg | Week 16 | 24772.35 | Standard Deviation 11970.153 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 75 mg | Week 20 | 10928.76 | Standard Deviation 7900.859 | Micrograms/liter (ug/L) |
| Serum Trough Concentrations of SHP647 Versus Time | SHP647 225 mg | Week 20 | 25582.98 | Standard Deviation 11767.775 | Micrograms/liter (ug/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01771809/results